Cargando…

A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity

PURPOSE: To look at how the absolute neutrophil count (ANC) is used by community oncologists as the main factor in ordering adjuvant mFOLFOX6 for colorectal cancer. This study reports on how this decision impacts chemotherapy delays, effects received dose intensity (RDI), and increases the use of gr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiarotto, James A, Dranitsaris, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141389/
https://www.ncbi.nlm.nih.gov/pubmed/34040446
http://dx.doi.org/10.2147/CMAR.S307713
_version_ 1783696354338406400
author Chiarotto, James A
Dranitsaris, George
author_facet Chiarotto, James A
Dranitsaris, George
author_sort Chiarotto, James A
collection PubMed
description PURPOSE: To look at how the absolute neutrophil count (ANC) is used by community oncologists as the main factor in ordering adjuvant mFOLFOX6 for colorectal cancer. This study reports on how this decision impacts chemotherapy delays, effects received dose intensity (RDI), and increases the use of granulocyte-colony-stimulating factor (G-CSF). METHODS: A retrospective chart review was conducted for all patients receiving adjuvant mFOLFOX6 for colorectal cancer at a two-site community hospital in Toronto, Ontario, Canada, between July 2013 and March 2019. Seven physicians treated 140 patients, who made 1636 clinic visits to receive 1461 cycles of prescribed chemotherapy. RESULTS: The mean ANC per physician associated with a decision to give chemotherapy ranged from 1.05×10(9)/L (95% CI 0.98–1.13×10(9)/L) to 1.5x10(9)/L with a decision to delay if the ANC was lower. Subsequent cycles were then supported by G-CSF with very similar ANC decision levels for dose delay. Physicians were more likely to prescribe chemotherapy with higher pretreatment ANC, r=0.3 (p<0.000). G-CSF was used in 24.6% of cycles and usage had grown to 44.2% by the 12th cycle; physician use ranged from 0.36% to 54.2% of cycles. Secondary prophylaxis was the indication in 94.7% of cases. There was an inverse relationship between the frequency of G-CSF use and the RDI of continuous infusion 5FU, r=−0.26 (p<0.001). There were delays for 8.8% of visits for cycles not supported by G-CSF and, surprisingly, 15.9% of visits for cycles supported by G-CSF. Neutropenia caused 61.6% of delays for chemotherapy cycles not supported by G-CSF and 44.1% for cycles supported by G-CSF. CONCLUSION: Physicians required a pretreatment ANC of 1.05–1.5×10(9)/L before prescribing mFOLFOX6 chemotherapy. When ANC was low, a dose delay and secondary prophylaxis with G-CSF failed to consistently achieve the much sought after ANC. This then caused more delay, reduced RDI and increased expense for both patients and the system. Fewer delays, less G-CSF and increased RDI would have resulted with reduced reliance on ANC and adoption of chemotherapy dose reduction.
format Online
Article
Text
id pubmed-8141389
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81413892021-05-25 A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity Chiarotto, James A Dranitsaris, George Cancer Manag Res Original Research PURPOSE: To look at how the absolute neutrophil count (ANC) is used by community oncologists as the main factor in ordering adjuvant mFOLFOX6 for colorectal cancer. This study reports on how this decision impacts chemotherapy delays, effects received dose intensity (RDI), and increases the use of granulocyte-colony-stimulating factor (G-CSF). METHODS: A retrospective chart review was conducted for all patients receiving adjuvant mFOLFOX6 for colorectal cancer at a two-site community hospital in Toronto, Ontario, Canada, between July 2013 and March 2019. Seven physicians treated 140 patients, who made 1636 clinic visits to receive 1461 cycles of prescribed chemotherapy. RESULTS: The mean ANC per physician associated with a decision to give chemotherapy ranged from 1.05×10(9)/L (95% CI 0.98–1.13×10(9)/L) to 1.5x10(9)/L with a decision to delay if the ANC was lower. Subsequent cycles were then supported by G-CSF with very similar ANC decision levels for dose delay. Physicians were more likely to prescribe chemotherapy with higher pretreatment ANC, r=0.3 (p<0.000). G-CSF was used in 24.6% of cycles and usage had grown to 44.2% by the 12th cycle; physician use ranged from 0.36% to 54.2% of cycles. Secondary prophylaxis was the indication in 94.7% of cases. There was an inverse relationship between the frequency of G-CSF use and the RDI of continuous infusion 5FU, r=−0.26 (p<0.001). There were delays for 8.8% of visits for cycles not supported by G-CSF and, surprisingly, 15.9% of visits for cycles supported by G-CSF. Neutropenia caused 61.6% of delays for chemotherapy cycles not supported by G-CSF and 44.1% for cycles supported by G-CSF. CONCLUSION: Physicians required a pretreatment ANC of 1.05–1.5×10(9)/L before prescribing mFOLFOX6 chemotherapy. When ANC was low, a dose delay and secondary prophylaxis with G-CSF failed to consistently achieve the much sought after ANC. This then caused more delay, reduced RDI and increased expense for both patients and the system. Fewer delays, less G-CSF and increased RDI would have resulted with reduced reliance on ANC and adoption of chemotherapy dose reduction. Dove 2021-05-19 /pmc/articles/PMC8141389/ /pubmed/34040446 http://dx.doi.org/10.2147/CMAR.S307713 Text en © 2021 Chiarotto and Dranitsaris. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Chiarotto, James A
Dranitsaris, George
A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity
title A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity
title_full A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity
title_fullStr A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity
title_full_unstemmed A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity
title_short A Community Hospital-Based Study: A Prespecified Neutrophil Count with Adjuvant mFOLFOX6 Associated with Increased Delays, Increased G-CSF Use, and Reduced Dose Intensity
title_sort community hospital-based study: a prespecified neutrophil count with adjuvant mfolfox6 associated with increased delays, increased g-csf use, and reduced dose intensity
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141389/
https://www.ncbi.nlm.nih.gov/pubmed/34040446
http://dx.doi.org/10.2147/CMAR.S307713
work_keys_str_mv AT chiarottojamesa acommunityhospitalbasedstudyaprespecifiedneutrophilcountwithadjuvantmfolfox6associatedwithincreaseddelaysincreasedgcsfuseandreduceddoseintensity
AT dranitsarisgeorge acommunityhospitalbasedstudyaprespecifiedneutrophilcountwithadjuvantmfolfox6associatedwithincreaseddelaysincreasedgcsfuseandreduceddoseintensity
AT chiarottojamesa communityhospitalbasedstudyaprespecifiedneutrophilcountwithadjuvantmfolfox6associatedwithincreaseddelaysincreasedgcsfuseandreduceddoseintensity
AT dranitsarisgeorge communityhospitalbasedstudyaprespecifiedneutrophilcountwithadjuvantmfolfox6associatedwithincreaseddelaysincreasedgcsfuseandreduceddoseintensity